The Pfizer Independent Medical Education Grant supports educational initiatives focused on the evidence-based safety contextualization of janus kinase inhibitors (JAKis) for the treatment of moderate-to-severe atopic dermatitis (AD).

Overview

This competitive program seeks to educate healthcare providers on the safety data context of JAKis in treating moderate-to-severe (M2S) atopic dermatitis. The education must be based on the totality of current literature advanced since the approvals of JAKis in this therapeutic area in 2022. Projects are expected to provide education to dermatologists, allergists, or other healthcare professionals involved in the care of adolescent and adult AD patients.

Funding and Benefits

• Funding Range: Individual projects requesting up to $75,000 USD will be considered.
• Total Estimated Budget: The estimated total available budget related to this Request for Proposals (RFP) is $150,000 USD.
• Award Structure: Two proposals will be awarded: one from the US and one from ex-US. Award amounts include direct costs, institutional overhead costs (capped at 28% per Pfizer policy), and indirect costs.
• Project Length: The maximum project length is 1 year.

Eligibility

The following criteria apply to potential applicants:

• Eligible Entities: Medical and professional schools; healthcare institutions (both large and small); professional organizations/medical societies; medical education companies; and other entities with a mission related to healthcare professional education and/or healthcare improvement.
• Exclusions: Only organizations are eligible to receive grants; individuals or medical practice groups are not eligible.
• Project Leadership: If the project involves multiple departments or institutions, all must have a relevant role, and the requesting organization must have a key role. The project/program lead must be an employee or contractor of the requesting organization.
• Geographic Scope: China, France, Germany, Italy, Japan, South Korea, Spain, and United States.

Research Areas or Activities

Potential applicants should design an initiative to synthesize existing medical literature on the safety data available for JAKis indicated for M2S AD and distill this into a concise, practical communication for the provider community. The educational initiative must be based on scientific evidence, including but not limited to:

• Retrospective or cohort analyses evaluating the background risk of adverse events of special interest (such as infections, cardiovascular events, or malignancies) in patients with M2S AD.
• Clinical trial safety data for JAKis use in M2S AD, including assessments of subpopulations (e.g., adolescents, elderly, or those with cardiovascular risk factors).
• Observational analyses, network meta-analyses, or other safety analyses, including comparative safety analyses or real-world assessments examining the rate of adverse events of special interest.

The primary area of interest is Dermatology – Atopic Dermatitis. The target audience includes Dermatologists (primary audience), Allergists, and Advanced Practice Providers, including Nurse Practice Providers and/or Physician Assistants practicing in dermatology and/or allergy.

Application Process and Timeline

Applications must be submitted through the designated online portal. Key dates and requirements include:

• Submission Deadline: (Specific date not provided, but the process requires submission).
• Review Process: The process involves review by the granting body.
• Anticipated Award Notification: (Specific date not provided).

Applicants must adhere to all guidelines provided in the official Request for Proposals (RFP).